Valuation: Epigenomics AG

Market Cap 1.23M 1.4M 1.13M 1.05M 1.99M 134M 2.03M 13.55M 5.27M 65.73M 5.27M 5.16M 227M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 12.19M 13.95M 11.21M 10.45M 19.81M 1.33B 20.11M 135M 52.3M 653M 52.36M 51.24M 2.25B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Change 5-day change 1-year change 3-year change Capi.($)
-1.92%+9.51% - - 1.4M
+0.95%-.--%+96.61%+12.37% 20.03B
-4.63%-5.64%+107.49%+129.05% 4.55B
-5.27%+1.10%+79.58%+217.22% 3.39B
+2.15%+5.68%-25.47%-39.18% 2.07B
+8.56%+1.41%+146.29%-39.30% 1.92B
-0.21%+1.28%+51.72%+243.82% 1.51B
-1.79%-2.89%+126.22%-51.45% 891M
+2.32%+6.54%-34.86%-16.56% 498M
-0.83%+8.52%-5.51% - 473M
Average -0.07%+0.84%+60.23%+57.00% 3.93B
Weighted average by Cap. -0.00%+0.51%+87.54%+49.59%

Financials

2024 2025
Net sales - 24K 27.45K 22.06K 20.56K 38.99K 2.61M 39.59K 265K 103K 1.28M 103K 101K 4.43M
Net income -3.35M -3.83M -3.08M -2.87M -5.45M -365M -5.53M -36.98M -14.38M -179M -14.39M -14.08M -618M -314K -359K -289K -269K -510K -34.2M -518K -3.46M -1.35M -16.81M -1.35M -1.32M -57.93M
Net Debt 10.46M 11.96M 9.61M 8.96M 16.99M 1.14B 17.24M 115M 44.84M 560M 44.89M 43.93M 1.93B 10.97M 12.55M 10.08M 9.39M 17.82M 1.19B 18.09M 121M 47.04M 587M 47.09M 46.08M 2.02B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
-

Annual profits - Rate of surprise